Serum lipid and apolipoprotein levels were associated to the Ki-67 and molecular classification of breast cancer

doi:10.3969/j.issn.1006-7795.2019.02.007

Abstract

Abstract: Objective To investigate the relationship between serum lipid and molecular types, Ki-67 level of breast cancer. Methods Total of 143 breast cancer patients who underwent the surgery from January 2012 to May 2017 were enrolled. The level of high density lipoprotein-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C), cholesterol (TC), apolipoprotein B (ApoB), apolipoprotein A (ApoA),and triglyceride (TG) were measured. The relationship between the above factors and the different molecular types of breast cancer was analyzed and discussed. Results The level of HDL-C, LDL-C, TC, ApoB and TG were significantly associated with different breast cancer subtypes (P<0.05). No significant difference of ApoA levels was observed in the different breast cancer subtypes (P>0.05). The levels of LDL-C, TC and ApoB were positively correlated with Ki-67 levels, while the levels of HDL-C was negatively correlated with Ki-67 level. However, The levels of ApoB and TG showed no relation with Ki-67 expression level. Conclusion Lipid metabolism is different in different breast cancer molecular subtypes. The serum lipid level is related to the expression level of Ki-67. High levels of TC and LDL-C and low level of HDL-C suggest poor prognosis in breast cancer.

Key words: breast cancer, molecular classification, serum lipid

CLC Number:

R737.9

Chen Nina, Fan Yichang, Shang Kun, Yang Jing, Cao Bangwei. Serum lipid and apolipoprotein levels were associated to the Ki-67 and molecular classification of breast cancer[J]. Journal of Capital Medical University, 2019, 40(2): 191-194.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2019.02.007

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2019/V40/I2/191

References

[1] Siegel R L, Miller K D, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1):7-30.
[2] Bustreo S, Osella-Abate S, Cassoni P, et al. Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation:a large case series study with a long-term follow-up[J]. Breast Cancer Res Treat, 216, 157(2):363-371.
[3] Xiang Q,Tang J, Luo Q, et al. In vitro study of anti-ER positive breast cancer effect and mechanism of 1,2,3,4-6-pentyl-O-galloyl-beta-d-glucose(PGG)[J].Biomed Pharmacother,2019,111:813-820.
[4] Goldhirsch A, Winer E P, Coates A S, et al. Personalizing the treatment of women with early breast cancer:highlights of the St Gallen International expert consensus on the primary therapy of early breast cancer 2013[J]. Ann Oncol, 2013, 24(9):2206-2223.
[5] Baek A E, Nelson E R. The contribution of cholesterol and its metabolites to the pathophysiology of breast cancer[J]. Horm Cancer, 2016, 7(4):219-228.
[6] Leignadier J, Dalenc F, Poirot M, et al. Improving the efficacy of hormone therapy in breast cancer:The role of cholesterol metabolism in SERM-mediated autophagy, cell differentiation and death[J]. Biochem Pharmacol, 2017,15(144):18-28.
[7] Tie G, Yan J, Khair L, et al. Hypercholesterolemia increases colorectal cancer incidence by reducing production of NKT and gammadelta T Cells from hematopoietic stem cells[J]. Cancer Res, 2017, 77(9):2351-2362.
[8] Geva S, Lazarev I, Geffen D B, et al. Hypertriglyceridemia in patients with metastatic breast cancer and treatment with capecitabine[J]. J Chemother, 2013, 25(3):176-180.
[9] Jeon J C, Park J, Park S, et al. Hypercholesterolemia is associated with a shorter time to castration-resistant prostate cancer in patients who have undergone androgen deprivation therapy[J]. World J Mens Health, 2016, 34(1):28-33.
[10] Simon A. Cholesterol metabolism and immunity[J]. N Engl J Med, 2014, 371(20):1933-1935.
[11] Beckwitt C H, Brufsky A, Oltvai Z N, et al. Statin drugs to reduce breast cancer recurrence and mortality[J]. Breast Cancer Res, 2018, 20(1):144.
[12] Liu B, Yi Z, Guan X, et al. The relationship between statins and breast cancer prognosis varies by statin type and exposure time:a meta-analysis[J]. Breast Cancer Res Treat, 2017, 164(1):1-11.
[13] Reiner Ž. Triglyceride-rich lipoproteins and novel targets for anti-atherosclerotic therapy[J]. Korean Circ J, 2018, 48(12):1097-1119.
[14] Kapil U, Bhadoria A S, Sareen N, et al. Total cholesterol and triglyceride levels in patients with breast cancer[J]. J Breast Cancer, 2013, 16(1):129-130.
[15] Seo S H, Kim K H, Oh S H, et al.Ki-67 labeling index as a prognostic marker in advanced stomach cancer[J].Ann Surg Treat Res,2019,96(1):27-33.
[16] 黄凌萍, 丁洁琼.乳腺浸润性导管癌组织中ER、PR、Ki-67、p53表达与超声造影特征的相关性研究[J].解放军医药杂志,2017,29(9):63-66.
[17] 马海明, 刘涛,刘晓康,等.乳腺癌组织Ki-67和HER2及PHH3表达与新辅助化疗疗效相关性分析[J].中华肿瘤防治杂志,2018,25(10):709-712.
[18] Mannell A. The role of Ki-67 in breast cancer[J]. S Afr J Surg, 2016, 54(2):10-13.